Filing Flows › Vaxart (VXRT) › Capital expenditures
Vaxart (VXRT) capital expenditures by quarter
Vaxart's capital expenditures were $371K in Q3 2026 (third quarter 2026), +960% from Q2 2026. Over the last 4 quarters it ranged from $1K (Q4 2025) to $371K (Q3 2026).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $371K | +960% | +217% |
| Q2 2026 | $35K | 35× | — |
| Q4 2025 | $1K | -99% | — |
| Q3 2025 | $117K | — | — |
Q3 2026 at a glance
Vaxart, Q3 2026: revenue $10.6M (-85% year over year), operating margin -162.7%, net loss $17.7M, operating cash flow $1.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Vaxart's capital expenditures?
Vaxart's capital expenditures were $371K in Q3 2026 (third quarter 2026), +960% from Q2 2026.
How has Vaxart's capital expenditures changed?
Over the last 4 quarters it ranged from $1K (Q4 2025) to $371K (Q3 2026).